360 related articles for article (PubMed ID: 16396651)
1. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
[TBL] [Abstract][Full Text] [Related]
2. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
Korte JM; Kaila T; Saari KM
Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG).
Ohno Y; Iga T; Yamada Y; Nagahara M; Araie M; Takayanagi R
Curr Eye Res; 2005 Apr; 30(4):319-28. PubMed ID: 16020262
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel.
Bonnin N; Nezzar H; Dubray C; Renault D; Olmiere C; Chiambaretta F
J Fr Ophtalmol; 2012 Jan; 35(1):9-16. PubMed ID: 21992993
[TBL] [Abstract][Full Text] [Related]
5. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.
Nieminen T; Lehtimäki T; Mäenpää J; Ropo A; Uusitalo H; Kähönen M
Scand J Clin Lab Invest; 2007; 67(2):237-45. PubMed ID: 17366003
[TBL] [Abstract][Full Text] [Related]
6. Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers.
Mundorf TK; Ogawa T; Inui N; Naka H; Novack GD; Crockett RS
Curr Med Res Opin; 2005 Mar; 21(3):369-74. PubMed ID: 15811205
[TBL] [Abstract][Full Text] [Related]
7. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
8. Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma.
Uusitalo H; Kähönen M; Ropo A; Mäenpää J; Bjärnhall G; Hedenström H; Turjanmaa V
Graefes Arch Clin Exp Ophthalmol; 2006 Nov; 244(11):1491-6. PubMed ID: 16628416
[TBL] [Abstract][Full Text] [Related]
9. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects.
Fuchsjager-Mayrl G; Markovic O; Losert D; Lucas T; Wachek V; Muller M; Schmetterer L
Mol Vis; 2005 Sep; 11():811-5. PubMed ID: 16205624
[TBL] [Abstract][Full Text] [Related]
11. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
Ishii Y; Nakamura K; Matsuki S; Uemura N; Muraguchi R; Nakagawa M; Nakano S; Nakatsuka K
J Clin Pharmacol; 2002 Sep; 42(9):1020-6. PubMed ID: 12211218
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
14. Effects of topical nipradilol and timolol maleate on intraocular pressure, facility of outflow, arterial blood pressure and pulse rate in dogs.
Maehara S; Ono K; Ito N; Tsuzuki K; Seno T; Yokoyama T; Yamashita K; Izumisawa Y; Kotani T
Vet Ophthalmol; 2004; 7(3):147-50. PubMed ID: 15091320
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
16. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.
Kaback M; Scoper SV; Arzeno G; James JE; Hua SY; Salem C; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2008 Oct; 115(10):1728-34, 1734.e1-2. PubMed ID: 18538406
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
19. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
Liu JH; Medeiros FA; Slight JR; Weinreb RN
Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
[TBL] [Abstract][Full Text] [Related]
20. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor.
Volotinen M; Mäenpää J; Kautiainen H; Tolonen A; Uusitalo J; Ropo A; Vapaatalo H; Aine E
Eur J Pharm Sci; 2009 Feb; 36(2-3):292-6. PubMed ID: 19013521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
